Extracts Are Under Pressure — Here's What That Means For Buyers
Extract pricing has started to diverge — not just by origin, but by spec. Standardised extracts (like 10:1 or 5% active) are holding firm or climbing, while off-spec or "fuzzy" grades are flooding the market at cut prices.
Buyers are stuck in a balancing act: justify cost to procurement, but avoid cutting too close to label claims.
The worst position?
Getting locked into a spec that no longer reflects market availability.
This is especially true in categories like nootropics and adaptogens, where regulatory clarity and labelling are already shaky.
At Invenex, we review extract grades against market shifts.
If you're sourcing ginseng, rhodiola, turmeric, or ashwagandha — now's the time to question the grade before you question the price.
